MX2022003593A - Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil. - Google Patents

Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.

Info

Publication number
MX2022003593A
MX2022003593A MX2022003593A MX2022003593A MX2022003593A MX 2022003593 A MX2022003593 A MX 2022003593A MX 2022003593 A MX2022003593 A MX 2022003593A MX 2022003593 A MX2022003593 A MX 2022003593A MX 2022003593 A MX2022003593 A MX 2022003593A
Authority
MX
Mexico
Prior art keywords
patient
fontan
svhd
performance
methods
Prior art date
Application number
MX2022003593A
Other languages
English (en)
Spanish (es)
Inventor
James L Yeager
David J Goldberg
Stephen M Paridon
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of MX2022003593A publication Critical patent/MX2022003593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022003593A 2019-09-24 2020-05-12 Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil. MX2022003593A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962905350P 2019-09-24 2019-09-24
US201962936497P 2019-11-16 2019-11-16
US202063023070P 2020-05-11 2020-05-11
PCT/US2020/032493 WO2021061203A1 (en) 2019-09-24 2020-05-12 Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions

Publications (1)

Publication Number Publication Date
MX2022003593A true MX2022003593A (es) 2022-09-19

Family

ID=75167062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003593A MX2022003593A (es) 2019-09-24 2020-05-12 Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.

Country Status (7)

Country Link
US (1) US12576081B2 (https=)
EP (1) EP4041242A4 (https=)
JP (2) JP2022550734A (https=)
AU (1) AU2020356193A1 (https=)
CA (1) CA3155861A1 (https=)
MX (1) MX2022003593A (https=)
WO (1) WO2021061203A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3227475A1 (en) * 2021-07-26 2023-02-02 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
CN119072312A (zh) * 2021-12-20 2024-12-03 美智恩制药公司 用于改善运动表现的方法和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
US7811244B2 (en) * 2004-03-23 2010-10-12 Georgia Tech Research Corp. Anatomical connection
PT1888074E (pt) 2005-06-10 2012-03-01 Dong A Pharm Co Ltd Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
JP2009509984A (ja) 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
WO2008151734A1 (en) 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
CA2784788A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
TN2017000029A1 (en) * 2014-08-12 2018-07-04 Mezzion Pharma Co Ltd Methods of improving myocardial performance in fontan patients using udenafil compositions

Also Published As

Publication number Publication date
JP2025118624A (ja) 2025-08-13
AU2020356193A1 (en) 2022-05-19
JP2022550734A (ja) 2022-12-05
CA3155861A1 (en) 2021-04-01
EP4041242A4 (en) 2023-10-18
US20240197736A1 (en) 2024-06-20
EP4041242A1 (en) 2022-08-17
US12576081B2 (en) 2026-03-17
WO2021061203A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
Georgiou et al. Systematic review of the mechanisms driving effective blood flow during adult CPR
MX2022003593A (es) Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.
Gamble-George et al. ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research
Galland et al. Swift recovery of severe hypoxemic pneumonia upon morbid obesity
Amran et al. Perspective chapter: physiology and pathology of the cardiovascular system
Lecerof Influence of body position on exercise tolerance, heart rate, blood pressure, and respiration rate in coronary insufficiency
Verrier et al. A canine model of acute coronary artery stenosis: effects of deliberate hypotension
Inagawa et al. Felypressin, but not epinephrine, reduces myocardial oxygen tension after an injection of dental local anesthetic solution at routine doses
Paul et al. Studies of pulmonary hypertension. IX. The effects of intravenous hexamethonium on pulmonary circulation in patients with mitral stenosis
JP2022550734A5 (https=)
Kawano et al. Torsades de pointes associated with takotsubo cardiomyopathy in an anorexia nervosa patient during emergence from general anesthesia
Lindell et al. Haemodynamic changes in chronic constrictive pericarditis during exercise and histamine infusion
Templeton et al. Surgical treatment of postinfarction ventricular aneurysms
Petrucci et al. Fetal right ventricular myocardial function is better preserved by fibrillatory arrest during fetal cardiac bypass
Burkett Heart rate, rhythm, and contractility
Taylor et al. Alternating fast and slow chest compression rates during CPR improved hemodynamics
Schreiber Validation of mitral regurgitation reversibility in patients with HeartMate 3 implantation
Powell et al. Abnormal Submaximal Cardiopulmonary Exercise Parameters Predicts Impaired Peak Exercise Performance In Sickle Cell Anemia Patients: 1463 Board# 271 May 31 900 AM-1030 AM
Ramirez-Marrero et al. Considering Cardiorespiratory Fitness Relative to Lean Body Mass in HIV+ compared with HIV-Hispanic Women: 1464 Board# 272 May 31 900 AM-1030 AM
Garg et al. Terlipressin induced ventricular tachycardia
MX2024007796A (es) Métodos y composiciones para mejorar el rendimiento en el ejercicio.
BEATTIE JR Pulmonary edema, etiology and therapy
Michalski et al. Does Estimated Cardiorespiratory Fitness Accurately Predict Directly Measured Vo2peak In Breast Cancer Survivors?: 1462 Board# 270 May 31 9: 00 AM-10: 30 AM
RU2680798C2 (ru) Способ оценки числа функционирующих кровеносных капилляров у человека (варианты)
Kim et al. A Comparative Study of the Postoperative Cardiac Performance after Repair of Congenital Heart Defects with Crystalloid and Blood Cardioplegic Solution